Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 15/2008

01.10.2008 | Adis Drug Profile

Ambrisentan

verfasst von: Jamie D. Croxtall, Susan J. Keam

Erschienen in: Drugs | Ausgabe 15/2008

Einloggen, um Zugang zu erhalten

Abstract

  • ▴ Elevated endothelin (ET)-1 levels are strongly correlated with the pathogenesis and prognosis of pulmonary arterial hypertension (PAH). Ambrisentan is an orally active, highly selective ETa receptor antagonist with >4000-fold higher selectivity over the ETb receptor.
  • ▴ In two large, well designed, 12-week, placebo-controlled, phase III trials (ARIES-1, n = 202 and ARIES-2, n = 192) in patients with PAH (WHO group I), ambrisentan 2.5–10 mg once daily significantly increased 6-minute walk distance by 31–59 m from baseline (primary outcome measure) versus placebo.
  • ▴ The incidence of clinical worsening (secondary outcome measure) was significantly delayed for the combined ambrisentan 5 mg once daily groups versus the combined placebo groups from ARIES-1 and -2.
  • ▴ At week 12, WHO functional class distribution was significantly improved with once-daily ambrisentan 5 mg, and Borg dyspnoea scores were significantly improved with ambrisentan 2.5–10 mg versus placebo in combined data from the ARIES-1 and -2 trials.
  • ▴ The beneficial effects of ambrisentan on exercise capacity, WHO functional class and Borg dyspnoea scores seen at 12 weeks were maintained at 48 weeks in the ARIES-E phase III extension trial (n = 361). One-year survival rates with ambrisentan were 95–97%.
  • ▴ Treatment with ambrisentan for up to 2.8 years was generally well tolerated in clinical trials.
Fußnoten
1
The use of trade names is for identification purposes only and does not imply endorsement.
 
Literatur
1.
Simonneau G, Galie N, Rubin L, et al. Clinical classification of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: S5–12CrossRef
2.
Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007 Jun; 131(6): 1917–28PubMedCrossRef
3.
Driscoll JA, Chakinala MM. Medical therapy for pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy 2008; 9(1): 65–81PubMedCrossRef
4.
Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004 Dec; 25(24): 2243–78
5.
6.
Hoeper MM. Drug treatment of pulmonary arterial hypertension: current and future agents. Drugs 2005; 65(10): 1337–54PubMedCrossRef
7.
Liu C, Chen J. Endothelin receptor antagonists for pulmonary hypertension. Cochrane Database of Systematic Reviews 2006; (2): CD004434
8.
National Pulmonary Hypertension Centres of the UK and Ireland. Consensus statement on the management of pulmonary hypertension in clinical parctice in the UK and Ireland. Heart 2008; 94: 1–41CrossRef
9.
D’Alonzo G, Barst R, Ayres S, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115: 343–9PubMed
10.
Channick RN, Sitbon O, Barst RJ, et al. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004 Jun 16; 43 (12 Suppl. S): 62–7SCrossRef
11.
Kirkby NS, Hadoke PW, Bagnall AJ, et al. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 2008 Mar; 153(6): 1105–19PubMedCrossRef
12.
Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008 Feb; 31(2): 407–15PubMedCrossRef
13.
Croom KF, Curran MP. Sildenafil: a review of its use in pulmonary arterial hypertension. Drugs 2008; 68(3): 383–97PubMedCrossRef
14.
Oldfield V, Lyseng-Williamson KA. Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis. Am J Cardiovasc Drug 2006; 6(3): 189–208CrossRef
15.
16.
Price LC, Howard LS. Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy. Am J Cardiovasc Drugs 2008; 8(3): 171–85PubMedCrossRef
17.
18.
Opitz CF, Ewert R, Kirch W, et al. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J 2008; 29(16): 1936–48PubMedCrossRef
19.
Giaid A. Nitric oxide and endothelin-1 in pulmonary hypertension. Chest 1998; 114: S208–12CrossRef
20.
21.
Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010–9PubMedCrossRef
22.
Leuchte H, Holzapfel M, Baumgartner R, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004; 43: 764–70PubMedCrossRef
23.
Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006; 129: 1313–21PubMedCrossRef
24.
Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005 Aug 2; 46(3): 529–35PubMedCrossRef
25.
Rubin L, Dufton C, Gerber M. Ambrisentan for pulmonary arterial hypertension. Future Cardiol 2005; 1(4): 425–32PubMedCrossRef
26.
Gerber MJ, Dufton C, Pentikis H, et al. Ambrisentan has no clinically relevant effect on the pharmacokinetics or pharmacodynamics of warfarin. Chest 2006 Oct 1; 130 Suppl. 4: 256
27.
Dufton C, Gerber MJ, Yin O, et al. No clinically relevant pharmacokinetic interaction between ambrisentan and sildenafil. Chest 2006 Oct 1; 130 Suppl. 4: 254
28.
Oudiz RJ, ARIES study group. Long-term ambrisentan therapy provides sustained benefit in patients with pulmonary arterial hypertension. Chest 2007 Oct; 132 Suppl. 4: 474
29.
Galie N, Keogh A, Frost A, et al. Ambrisentan long-term safety and efficacy in pulmonary arterial hypertension: one year follow-up [abstract no. M14227]. Proc Am Thorac Soc 2005; 2 (Abstr. Suppl.): A299
30.
Badesch D, Zwicke D, Keogh AM, et al. Long-term benefits of ambrisentan in patients with pulmonary arterial hypertension associated with connective tissue diseases [abstract]. Arthritis Rheum 2005 Sep; 52 (Suppl. 9): 166
31.
Gilead Sciences. ARIES: ambrisentan in patients with moderate to severe pulmonary aterial hypertension (PAH) [ClinicalTrials.gov identifier NCT00091598]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​clinicaltrials.​gov [Accessed 2008 Jun 24]
32.
Gilead Sciences. Study of BSF 208075 evaluating exercise capacity in patients with pulmonary arterial hypertension [ClinicalTrials.gov identifier NCT00046319]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​clinicaltrials.​gov [Accessed 2008 Jun 24]
33.
Gilead Sciences. A long term study of ambrisentan in pulmonary arterial hypertension subjects having completed AMB-320 or AMB-321 [ClinicalTrials.gov identifier NCT00578786]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​clinicaltrials.​gov [Accessed 2008 Jun 24]
34.
Myogen. Phase 2 extension study of ambrisentan in pulmonary arterial hypertension [ClinicalTrials.gov identifier NCT00424021]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​clinicaltrials.​gov [Accessed 2008 Jun 24]
35.
Olschewski H, and The Ambrisentan in PAH Study Group. Long-term safety and tolerance of ambrisentan in patients with pulmonary arterial hypertension [abstract no. 1335]. Eur Respir J Suppl 2005 Sep; 26 Suppl. 49: 205
36.
McGoon M, Frost A, Rubin L, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxesntan due to liver function abnormalities: 1 year follow-up. Am J Respir Crit Care Med 2007 Apr; 175 Suppl. 4: 301
37.
Myogen. Phase 2 study of ambrisentan for liver function test rescue in pulmonary arterial hypertension [ClinicalTrials.gov identifier NCT00423592]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​clinicaltrials.​gov [Accessed 2008 Jun 24]
38.
McGoon M, Frost A, Oudiz R, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest. Epub 2008 Sep 23
39.
Metadaten
Titel
Ambrisentan
verfasst von
Jamie D. Croxtall
Susan J. Keam
Publikationsdatum
01.10.2008
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 15/2008
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200868150-00008

Weitere Artikel der Ausgabe 15/2008

Drugs 15/2008 Zur Ausgabe

Therapy In Practice

The Short-Term Medical Management of Non-Variceal Upper Gastrointestinal Bleeding

Review Article

New Drugs for Type 2 Diabetes Mellitus

Review Article

Topical Fenticonazole in Dermatology and Gynaecology

Review Article

Pathogenesis and Treatment of Pruritus in Cholestasis

Adis Drug Evaluation

Pregabalin

Current Opinion

Androgen Replacement Therapy in Androgen-Deficient Women with Hypopituitarism